Differentiation of Prior SARS-CoV-2 Infection and Postacute Sequelae by Standard Clinical Laboratory Measurements in the RECOVER Cohort.
Link: https://doi.org/10.7326/M24-0737
Authors: Erlandson, Kristine M; Geng, Linda N; Selvaggi, Caitlin A; Thaweethai, Tanayott; Chen, Peter; Erdmann, Nathan B; Goldman, Jason D; Henrich, Timothy J; Hornig, Mady; Karlson, Elizabeth W; Katz, Stuart D; Kim, C; Cribbs, Sushma K; Laiyemo, Adeyinka O; Letts, Rebecca; Lin, Janet Y; Marathe, Jai; Parthasarathy, Sairam; Patterson, Thomas F; Taylor, Brittany D; Duffy, Elizabeth R; Haack, Monika; Julg, Boris; Maranga, Gabrielle; Hernandez, Carla; Singer, Nora G; Han, Jenny; Pemu, Priscilla; Brim, Hassan; Ashktorab, Hassan; Charney, Alexander W; Wisnivesky, Juan; Lin, Jenny J; Chu, Helen Y; Go, Minjoung; Singh, Upinder; Levitan, Emily B; Goepfert, Paul A; Nikolich, Janko Ž; Hsu, Harvey; Peluso, Michael J; Kelly, J Daniel; Okumura, Megumi J; Flaherman, Valerie J; Quigley, John G; Krishnan, Jerry A; Scholand, Mary Beth; Hess, Rachel; Metz, Torri D; Costantine, Maged M; Rouse, Dwight J; Taylor, Barbara S; Goldberg, Mark P; Marshall, Gailen D; Wood, Jeremy; Warren, David; Horwitz, Leora; Foulkes, Andrea S; McComsey, Grace A; ,
Abstract: There are currently no validated clinical biomarkers of postacute sequelae of SARS-CoV-2 infection (PASC). To investigate clinical laboratory markers of SARS-CoV-2 and PASC. Propensity score-weighted linear regression models were fitted to evaluate differences in mean laboratory measures by prior infection and PASC index (≥12 vs. 0). (ClinicalTrials.gov: NCT05172024). 83 enrolling sites. RECOVER-Adult cohort participants with or without SARS-CoV-2 infection with a study visit and laboratory measures 6 months after the index date (or at enrollment if >6 months after the index date). Participants were excluded if the 6-month visit occurred within 30 days of reinfection. Participants completed questionnaires and standard clinical laboratory tests. Whether differences in laboratory markers represent consequences of or risk factors for SARS-CoV-2 infection could not be determined. Overall, no evidence was found that any of the 25 routine clinical laboratory values assessed in this study could serve as a clinically useful biomarker of PASC. National Institutes of Health.